{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T23:55:18Z","timestamp":1780703718240,"version":"3.54.1"},"reference-count":34,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>There is an unmet need to examine antitumor immune responses and predictive biomarkers in the peripheral blood to guide effective combination immunotherapies in classical Hodgkin lymphoma (cHL). We sought to evaluate T-cell specific immune responses as well as cytokine and chemokine profiles including levels of soluble CD30 (sCD30), sCD163, and thymus and activation-regulated chemokine (TARC) in relation to event-free survival in patients with cHL. The Children\u2019s Oncology Group (COG) clinical trial AHOD1331 was a randomized phase 3 trial for patients with newly diagnosed high-risk cHL, aged 2 to 21 years, which compared standard chemotherapy and doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) with brentuximab vedotin (Bv) and AVE-PC with response adapted radiation. Our results demonstrate that chemotherapy with or without addition of anti-CD30 antibody-drug conjugate Bv is associated with a favorable cytokine environment for cellular and immunotherapies. Treatment of cHL on both arms increased tumor antigen-specific T-cell responses and resulted in decreased levels of sCD30, sCD163, and TARC. We demonstrate that treatment of cHL on COG AHOD1331 produced an environment that favors antitumor immune response, which may aid in application of further cellular and immunotherapies targeting cHL. This trial was registered at www.ClinicalTrials.gov as #NCT02166463.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016797","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T14:43:11Z","timestamp":1758724991000},"page":"183-191","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9324-7314","authenticated-orcid":false,"given":"Keri","family":"Toner","sequence":"first","affiliation":[{"name":"1Center for Cancer and Immunology Research Children's National Hospital; and Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay A.","family":"Renfro","sequence":"additional","affiliation":[{"name":"2Division of Biostatistics, University of Southern California and Children\u2019s Oncology Group, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5530-0201","authenticated-orcid":false,"given":"Hema","family":"Dave","sequence":"additional","affiliation":[{"name":"1Center for Cancer and Immunology Research Children's National Hospital; and Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Pezzella","sequence":"additional","affiliation":[{"name":"1Center for Cancer and Immunology Research Children's National Hospital; and Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglin","family":"Pei","sequence":"additional","affiliation":[{"name":"3Department of Biostatistics, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Giulino-Roth","sequence":"additional","affiliation":[{"name":"4Department of Pediatrics, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terzah","family":"Horton","sequence":"additional","affiliation":[{"name":"5Department of Pediatrics, Texas Children\u2019s Hospital, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8919-467X","authenticated-orcid":false,"given":"Frank G.","family":"Keller","sequence":"additional","affiliation":[{"name":"6Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta\/Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara M.","family":"Kelly","sequence":"additional","affiliation":[{"name":"7Roswell Park Comprehensive Cancer Center\/Department of Pediatrics, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon M.","family":"Castellino","sequence":"additional","affiliation":[{"name":"6Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta\/Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5140-9090","authenticated-orcid":false,"given":"Catherine M.","family":"Bollard","sequence":"additional","affiliation":[{"name":"1Center for Cancer and Immunology Research Children's National Hospital; and Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"issue":"suppl 6","key":"2026012009164232500_bib1","doi-asserted-by":"crossref","first-page":"e30580","DOI":"10.1002\/pbc.30580","article-title":"Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma","volume":"70","author":"Castellino","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"18","key":"2026012009164232500_bib2","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2206660","article-title":"Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin's lymphoma","volume":"387","author":"Castellino","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"2026012009164232500_bib3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"2026012009164232500_bib4","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"key":"2026012009164232500_bib5","doi-asserted-by":"crossref","first-page":"1301437","DOI":"10.3389\/fonc.2023.1301437","article-title":"Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas","volume":"13","author":"Li","year":"2023","journal-title":"Front Oncol"},{"issue":"9","key":"2026012009164232500_bib6","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.4049\/jimmunol.165.9.5105","article-title":"CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis","volume":"165","author":"Muta","year":"2000","journal-title":"J Immunol"},{"issue":"1","key":"2026012009164232500_bib7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0966-3274(03)00014-5","article-title":"CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1\/TH2 response","volume":"12","author":"Pellegrini","year":"2003","journal-title":"Transpl Immunol"},{"issue":"14","key":"2026012009164232500_bib8","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","article-title":"Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment","volume":"29","author":"Steidl","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026012009164232500_bib9","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3390\/cancers13040884","article-title":"Biology and clinical applicability of plasma thymus and activation-regulated chemokine (TARC) in classical Hodgkin lymphoma","volume":"13","author":"Zijtregtop","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2026012009164232500_bib10","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","article-title":"Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed Hodgkin lymphoma","volume":"36","author":"Bollard","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026012009164232500_bib11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/bloodadvances.2021005343","article-title":"Tumor associated antigen specific T cells with nivolumab are safe and persist in vivo in relapsed\/refractory Hodgkin lymphoma","volume":"6","author":"Dave","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"2026012009164232500_bib12","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1038\/s41375-022-01717-8","article-title":"Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP","volume":"36","author":"Driessen","year":"2022","journal-title":"Leukemia"},{"issue":"16","key":"2026012009164232500_bib13","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2018-08-870915","article-title":"Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study","volume":"133","author":"Hsi","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2026012009164232500_bib14","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/bjh.14317","article-title":"Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC","volume":"175","author":"Plattel","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"2026012009164232500_bib15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ajh.23361","article-title":"Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma","volume":"88","author":"Sauer","year":"2013","journal-title":"Am J Hematol"},{"issue":"4","key":"2026012009164232500_bib16","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/hon.2775","article-title":"Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy","volume":"38","author":"Viviani","year":"2020","journal-title":"Hematol Oncol"},{"issue":"1","key":"2026012009164232500_bib17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/jha2.41","article-title":"Plasma thymus and activation-regulated chemokine (TARC) as diagnostic marker in pediatric Hodgkin lymphoma","volume":"1","author":"Zijtregtop","year":"2020","journal-title":"EJHaem"},{"issue":"8","key":"2026012009164232500_bib18","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1182\/blood.V91.8.3011.3011_3011_3016","article-title":"Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome","volume":"91","author":"Nadali","year":"1998","journal-title":"Blood"},{"issue":"9","key":"2026012009164232500_bib19","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1182\/blood.V77.9.1983.1983","article-title":"Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease","volume":"77","author":"Gause","year":"1991","journal-title":"Blood"},{"issue":"18","key":"2026012009164232500_bib20","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1158\/1078-0432.CCR-13-0955","article-title":"Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy","volume":"19","author":"Weber","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2026012009164232500_bib21","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/mt.2011.167","article-title":"Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma","volume":"19","author":"Gerdemann","year":"2011","journal-title":"Mol Ther"},{"issue":"13","key":"2026012009164232500_bib22","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.20.02224","article-title":"T-cell therapy for lymphoma using nonengineered multiantigen-targeted T cells is safe and produces durable clinical effects","volume":"39","author":"Vasileiou","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026012009164232500_bib23","author":"Team RC","year":"2025"},{"issue":"7","key":"2026012009164232500_bib24","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1158\/1055-9965.EPI-16-1012","article-title":"Elevated serum levels of sCD30 and IL6 and detectable IL10 precede classical Hodgkin lymphoma diagnosis","volume":"26","author":"Levin","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"2026012009164232500_bib25","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1158\/1078-0432.CCR-12-2693","article-title":"Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma","volume":"19","author":"Jones","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2026012009164232500_bib26","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1158\/2326-6066.CIR-23-0547","article-title":"T cell states, repertoire and function in classical Hodgkin lymphoma revealed through single-cell analyses","volume":"12","author":"Chen","year":"2024","journal-title":"Cancer Immunol Res"},{"issue":"22","key":"2026012009164232500_bib27","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2018-07-863654","article-title":"EBV\/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation","volume":"132","author":"McLaughlin","year":"2018","journal-title":"Blood"},{"issue":"26","key":"2026012009164232500_bib28","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/bloodadvances.2017009886","article-title":"Developing T-cell therapies for lymphoma without receptor engineering","volume":"1","author":"Grant","year":"2017","journal-title":"Blood Adv"},{"issue":"9","key":"2026012009164232500_bib29","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Invest"},{"issue":"22","key":"2026012009164232500_bib30","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.2023020959","article-title":"Elevated serum TARC levels precede classic Hodgkin lymphoma diagnosis by several years","volume":"142","author":"Diepstra","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2026012009164232500_bib31","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ijc.11301","article-title":"Imbalances of chemokines, chemokine receptors and cytokines in Hodgkin lymphoma: classical Hodgkin lymphoma vs. Hodgkin-like ATLL","volume":"106","author":"Ohshima","year":"2003","journal-title":"Int J Cancer"},{"issue":"5","key":"2026012009164232500_bib32","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2141.2007.06964.x","article-title":"Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22","volume":"140","author":"Niens","year":"2008","journal-title":"Br J Haematol"},{"issue":"1","key":"2026012009164232500_bib33","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bjh.18473","article-title":"Thymus and activation-regulated chemokine (TARC) as treatment response marker for paediatric Hodgkin lymphoma: a pilot study","volume":"200","author":"Zijtregtop","year":"2023","journal-title":"Br J Haematol"},{"issue":"18","key":"2026012009164232500_bib34","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1056\/NEJMe2211587","article-title":"Are we too reliant on radiation therapy for children with Hodgkin's lymphoma?","volume":"387","author":"Roschewski","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/183\/2478853\/blooda_adv-2025-016797-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/183\/2478853\/blooda_adv-2025-016797-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:16:56Z","timestamp":1768918616000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/1\/183\/547433\/Tumor-specific-immune-responses-and-biomarkers-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016797","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,13]]},"published":{"date-parts":[[2026,1,2]]}}}